

2021 -2022 Cancer Communications Committee

All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution

Name	Subcommittee	Employment	Leadership	Stock and Other Ownership Interests	Honoraria	Consulting or Advisory Role	Speakers' Bureau	Research Funding	Patents, Royalties, Other Intellectual Property	Expert Testimony	Travel, Accommodations, Expenses	Other Relationship	(OPTIONAL) Uncompensated Relationships	(OPTIONAL) Open Payments Link
Muhammad S. Beg						Array BioPharma AstraZeneca/MedImmune Cancer Commons Foundation Medicine Ipsen Legend Biotech		AstraZeneca/MedImmune (Inst) Bristol-Myers Squibb (Inst) Five Prime Therapeutics (Inst) Genentech (Inst) Immunesensor (Inst) MedImmune (Inst) Merck Serono (Inst) Tolero Pharmaceuticals (Inst)						
Lauren A. Byers						Abbvie Alethia AstraZeneca Bristol-Myers Squibb Debiopharm Group Genentech Genmab Jazz Pharmaceuticals Merck Pfizer PharmaMar Sierra Oncology Tolero Pharmaceuticals		AstraZeneca (Inst) Genmab (Inst) Sierra Oncology Tolero Pharmaceuticals						
Elizabeth A. Comen		Survivornet		Survivornet.com	ClearView Healthcare Partners Decision Resources Gerson Lehrman Group Grey Global Group Kantar Health Kantar Health Navigant Consulting Pfizer Pfizer Pfizer	Bristol-Myers Squibb Genentech HERON Novartis Novartis Novartis Pfizer Pfizer Pfizer		Hoffmann La Roche			Novartis Pfizer Pfizer			
Robert Dreicer						Astellas Pharma AstraZeneca AVEO Bayer bristol -Myers Squibb EMD Serono Exelixis Hinova Pharmaceuticals Infinity Janssen Oncology Merck Myovant Myovant Sciences Pfizer Propella Seattle Genetics Veru		Bristol-Myers Squibb (Inst) Exelixis (Inst) Novartis (Inst) Seattle Genetics (Inst)						
Cathy Eng						Bayer Health Gilead/Forty Seven GlaxoSmithKline Hookipa Biotech Mirati Therapeutics natera Pfizer		elevar fruquitinib Merck Pfizer						

Rita Nanda					Aduro Cardinal Health Cardinal Health Clovis Oncology Fujifilm G1 Therapeutics Genentech/Roche Immunomedics Ionis ITeos Therapeutics Macrogenics Merck OncoSec Pfizer Seattle Genetics	Arvinas (Inst) AstraZeneca (Inst) Celgene (Inst) Corcept Therapeutics (Inst) Genentech/Roche (Inst) Immunomedics (Inst) Merck (Inst) OBI Pharma (Inst) Odonate Therapeutics (Inst) OncoSec (Inst) Pfizer (Inst) Seattle Genetics (Inst) Taiho Oncology (Inst)			G1 Therapeutics			
Olatoyosi Odenike					Abbvie BMS Bristol-Myers Squibb/Celgene (Inst) Celgene CTI Biopharma Impact Biomedicines Novartis Taiho Threadwell therapeutics	Abbvie (Inst) Agiros (Inst) Aprea AB (Inst) Astex Pharmaceuticals (Inst) AstraZeneca (Inst) Celgene (Inst) CTI BioPharma Corp (Inst) Incyte (Inst) Janssen Oncology (Inst) Kartos (Inst) NS Pharma (Inst) Oncothyrapy (Inst)						
Nathan A. Pennell					Amgen AstraZeneca Boehringer Ingelheim Bristol-Myers Squibb Cota Healthcare G1 Therapeutics Genentech Janssen Oncology Lilly Merck Mirati Therapeutics Pfizer Sanofi/Regeneron Viosera Xencor	Altor BioScience (Inst) AstraZeneca (Inst) Bristol-Myers Squibb (Inst) Genentech (Inst) Heat Biologics (Inst) Jounce Therapeutics (Inst) Loxo (Inst) Merck (Inst) Mirati Therapeutics (Inst) Sanofi (Inst) Spectrum Pharmaceuticals (Inst) WindMIL (Inst)						
Elizabeth R. Plimack					Astellas Pharma AstraZeneca/MedImmune Aveo Bristol-Myers Squibb/Medarex Calithera Biosciences Calithera Biosciences Genentech Infinity Pharmaceuticals Janssen MEI Pharma Merck Pfizer Pfizer Regeneron Seattle Genetics	Astellas Pharma (Inst) Bristol-Myers Squibb (Inst) Genentech/Roche (Inst) Merck Sharp & Dohme (Inst)	# U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)					
Sonali M. Smith					Abbvie/Genentech ADC Therapeutics Bayer Bristol-Myers Squibb/Celgene Gilead/Forty Seven Janssen Oncology Karyopharm Therapeutics MorphoSys TG Therapeutics	Acerta Pharma/AstraZeneca Celgene Forty Seven Novartis Pharmacyclics/Janssen Portola Pharmaceuticals TG Therapeutics			Karyopharm Therapeutics			

Corey W. Speers						Exact Sciences			<p>#Compositions and Methods for the Analysis of Radiosensitivity, UM-33550/US-1, Coinventor, Submitted on 09/2013</p> <p>#Methods and Genomic Classifiers for Prognosis of Breast Cancer and Predicting Benefit from Adjuvant Radiotherapy</p>					
-----------------	--	--	--	--	--	----------------	--	--	---	--	--	--	--	--